日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world treatment patterns and outcomes among patients initiating sequential regorafenib and trifluridine/tipiracil ± bevacizumab in patients with metastatic colorectal cancer in a US community setting (SEQRT2)

美国社区环境中转移性结直肠癌患者接受序贯瑞戈非尼和三氟尿苷/替吡嘧啶±贝伐单抗治疗的真实世界治疗模式和结果(SEQRT2)

Bekaii-Saab, Tanios; Sruti, Ila; Shi, Junxin; Dai, Wei; Patton, Gregory; Appukkuttan, Sreevalsa; Hocum, Brian; Katta, Arvind; Babajanyan, Svetlana; Cosgrove, David

Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States

美国社区泌尿外科机构中转移性激素敏感性前列腺癌双药或三药疗法的应用

Lowentritt, Benjamin; Appukkuttan, Sreevalsa; Lazarou, Nicholas; O'Donnell, Lorraine; Eller, James; Grant, Katie; Arango-Hisijara, Israel; Kalayeh, Bashir; Curry, Lauren; Himes, Audrey; Jhaveri, Jay; Hamilton, Joelle

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

美国肿瘤治疗领域应用下一代测序技术的障碍和促进因素:系统性综述

Ferreira-Gonzalez, Andrea; Ko, Gilbert; Fusco, Nicole; Stewart, Fiona; Kistler, Kristin; Appukkuttan, Sreevalsa; Hocum, Brian; Allen, Stefan M; Babajanyan, Svetlana

Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers

NTRK融合阳性实体瘤患者的临床特征和治疗模式:美国学术癌症中心的多中心队列研究

Willis, Connor; Au, Trang; Hejazi, Andre; Griswold, Cassia; Schabath, Matthew B; Thompson, Jonathan; Malhotra, Jyoti; Federman, Noah; Ko, Gilbert; Appukkuttan, Sreevalsa; Warnock, Neil; Kong, Sheldon X; Hocum, Brian; Brixner, Diana; Stenehjem, David

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer

退伍军人非转移性去势抵抗性前列腺癌的生存结果与种族和民族的关系

Rasmussen, Kelli M; Patil, Vikas; Li, Chunyang; Yong, Christina; Appukkuttan, Sreevalsa; Grossman, Jamie Partridge; Jhaveri, Jay; Halwani, Ahmad S

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

美国接受阿帕鲁胺或恩扎鲁胺治疗的非转移性去势抵抗性前列腺癌患者的真实世界不良事件负担

Hussain, Arif; Jiang, Shan; Varghese, Della; Appukkuttan, Sreevalsa; Kebede, Nehemiah; Gnanasakthy, Kajan; Macahilig, Cynthia; Waldeck, Reg; Corman, Shelby

Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis

美国滤泡性淋巴瘤的治疗模式:一项理赔分析

Huntington, Scott F; Appukkuttan, Sreevalsa; Wang, Wenyi; Du, Yuxian; Hopson, Sari; Babajanyan, Svetlana

Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center

镭-223治疗转移性去势抵抗性前列腺癌:美国一家三级肿瘤中心的回顾性研究

McKay, Rana R; Silver, Rebecca; Bhak, Rachel H; Korves, Caroline; Cheng, Mu; Appukkuttan, Sreevalsa; Simmons, Stacey J; Duh, Mei Sheng; Taplin, Mary-Ellen

Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings

社区与学术机构中接受镭-223治疗的转移性去势抵抗性前列腺癌患者的临床结果、管理和治疗模式比较

Sartor, Oliver; Appukkuttan, Sreevalsa; Weiss, Jeffrey; Tsao, Che-Kai

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer

达罗鲁胺治疗非转移性去势抵抗性前列腺癌的预算影响分析

Appukkuttan, Sreevalsa; Farej, Ryan; Miles, LaStella; Purser, Molly; Wen, Lonnie